Hensler Surgical Products v. Tobra Medical: Surgical Bone Basket Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Hensler Surgical Products, LLC v. Tobra Medical, Inc. |
| Case Number | 7:19-cv-00240 |
| Court | North Carolina Eastern District Court |
| Duration | Dec 2019 – Apr 2024 4 years 4 months |
| Outcome | Dismissal with Prejudice — Each Party Bears Costs |
| Patents at Issue | |
| Accused Products | Tobra Medical’s bone basket product and similar others |
Case Overview
The Parties
⚖️ Plaintiff
A surgical device company with intellectual property focused on orthopedic and surgical instrumentation, holding patents over specialized bone-related surgical product designs.
🛡️ Defendant
A medical device company whose bone basket product was alleged to constitute a “knock-off” of Hensler’s patented technology.
Patents at Issue
This lawsuit involved a utility patent covering design and functional innovations in bone basket instrumentation, a niche but commercially critical segment of the surgical device market. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US10493183B2 — Surgical bone basket technology for orthopedic and surgical procedures.
Developing a new surgical device?
Check if your design might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case concluded via **stipulated dismissal with prejudice** pursuant to Fed. R. Civ. P. 41(a)(1)(A)(ii). Both Hensler Surgical Products and Tobra Medical jointly agreed to permanently bar Hensler from reasserting the same claims against Tobra. Crucially, **each party bears its own attorneys’ fees, expenses, and costs**, with no damages awarded or injunctive relief granted by judicial ruling.
Key Legal Issues
While specific legal theories were not publicly detailed, the mutual cost-bearing structure and the “with prejudice” designation are analytically significant. This outcome often suggests either a confidential settlement, or that the parties concluded continued litigation costs outweighed potential recoveries or faced sufficient risks to incentivize mutual disengagement. The absence of a published claim construction order means this case does not establish binding precedent regarding the scope of US10493183B2’s claims, but its resolution method is a common strategic exit in complex medical device patent disputes.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in surgical device design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all active surgical device patents in this technology space
- See which companies are most active in medical device patents
- Understand claim construction patterns for bone basket technology
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Surgical bone basket technology
1 Patent at Issue
US10493183B2 remains active
Design-Around Options
Possible with expert analysis
✅ Key Takeaways
Rule 41(a)(1)(A)(ii) stipulated dismissals with prejudice offer strategic finality without judicial burden — understand when to deploy them.
Search related case law →Four-year district court litigation without a published merits ruling signals high case complexity or evolving commercial dynamics.
Explore precedents →Surgical device design teams should conduct FTO reviews against bone basket patent portfolios before commercialization.
Start FTO analysis for my product →“Knock-off” product allegations in competitor litigation signal aggressive IP enforcement postures — differentiation strategies are essential.
Try AI patent drafting →Frequently Asked Questions
The case centered on U.S. Patent No. US10493183B2 (Application No. US16/393599), covering surgical bone basket technology.
Both parties jointly stipulated to dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii), with each bearing its own costs. The specific commercial or legal motivations were not publicly disclosed.
Hensler is permanently barred from reasserting these specific claims against Tobra Medical. However, US10493183B2 remains an enforceable patent that could be asserted against other market participants.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
PatSnap IP Intelligence Team
Patent Research & Competitive Intelligence · PatSnap
This analysis was produced by the PatSnap IP Intelligence Team — a group of patent analysts, IP strategists, and data scientists who work daily with PatSnap’s global patent database of over 2 billion structured data points across patents, litigation records, scientific literature, and regulatory filings.
The team specialises in tracking landmark litigation outcomes, translating complex court rulings into actionable IP strategy, and identifying the competitive intelligence implications for R&D and legal teams. All case analysis is grounded in primary sources: official court records, USPTO filings, and Federal Circuit opinions.
References
- U.S. Patent No. US10493183B2 — Google Patents
- PACER — Case No. 7:19-cv-00240 filings
- Cornell Legal Information Institute — Fed. R. Civ. P. 41
- U.S. Patent and Trademark Office — Patent Resources
- U.S. District Court for the Eastern District of North Carolina
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.
📑 Table of Contents
🚀 PatSnap Eureka IP Tools
🔍Novelty Search
Find prior art instantly
Patent Drafting
AI-assisted claim writing
FTO Analysis
Assess infringement risk
Concerned About Your Product’s IP Risk?
Don’t wait for litigation. Check your medical device’s freedom to operate now with AI-powered analysis.
Run FTO for My Product